- Tegaserod
-
- $31.00
-
2026-08-20
- CAS:145158-71-0
- Purity: 99.20%
- Supply Ability: 10g
- Tegaserod
-
- $1.00
-
2026-02-02
- CAS:145158-71-0
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 50tons
- Tegaserod
-
- $15.00
-
2021-08-12
- CAS:145158-71-0
- Min. Order: 1KG
- Purity: 99%+ HPLC
|
| | Tegaserod Basic information |
| Product Name: | Tegaserod | | Synonyms: | TEGASEROD;2-[(5-methoxy-1h-indol-3-yl)methylene]-n-pentylhydrazine-carboximidamide;Tegaserode;Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-;Tegaserod USP/EP/BP;Tegaserod 13CD3Q: What is
Tegaserod 13CD3 Q: What is the CAS Number of
Tegaserod 13CD3;Tegaserod D10Q: What is
Tegaserod D10 Q: What is the CAS Number of
Tegaserod D10;Tegaserod D11 (Major-D10)Q: What is
Tegaserod D11 (Major-D10) Q: What is the CAS Number of
Tegaserod D11 (Major-D10) | | CAS: | 145158-71-0 | | MF: | C16H23N5O | | MW: | 301.39 | | EINECS: | | | Product Categories: | | | Mol File: | 145158-71-0.mol |  |
| | Tegaserod Chemical Properties |
| Melting point | 155° | | Boiling point | 470.6±48.0 °C(Predicted) | | density | 1.18 | | storage temp. | 2-8°C | | form | Solid | | pka | 15.81±0.30(Predicted) | | color | White to off-white | | CAS DataBase Reference | 145158-71-0(CAS DataBase Reference) |
| | Tegaserod Usage And Synthesis |
| Uses | Treatment of gastrointestinal motility disorders
(selective serotonin 5HT4antagonist). | | Indications | Tegaserod (Zelnorm) is serotonin-4 (5-HT4) receptor agonists that stimulate GI motility. | | Definition | ChEBI: Tegaserod is a member of guanidines, a carboxamidine, a member of hydrazines and a member of indoles. It has a role as a serotonergic agonist and a gastrointestinal drug. | | Brand name | Zelmac (Novartis). | | Clinical Use | Tegaserod is being developed as a treatment for constipation-
predominant irritable bowel syndrome (IBS).
Within the first week, patients treated with tegaserod
had significant improvements in abdominal pain and discomfort,
constipation, and overall well-being. Efficacy
was maintained throughout the treatment period.
Tegaserod also demonstrated significant improvements
in the three bowel-related assessments (stool frequency,
stool consistency, and straining) within the first week,
and these improvements were sustained throughout the
treatment period. The most common adverse events reported
thus far are headache and diarrhea. |
| | Tegaserod Preparation Products And Raw materials |
|